Document is current
Any future updates will be listed below
-
Authors
Eskiocak, Onur
Gewolb, Joseph
Shah, Vyom https://orcid.org/0000-0001-6874-5285
Rouse, James A. https://orcid.org/0009-0005-4262-2363
Chowdhury, Saria
Akyildiz, Erdogan O.
Fernández-Maestre, Inés
Boyer, Jacob A.
Filliol, Aveline
Harris, Alexander S.
Utama, Raditya https://orcid.org/0000-0002-0055-2548
Guo, Guangran
Castro-Hernández, Carolina https://orcid.org/0000-0003-0008-151X
Nnuji-John, Emmanuella
Chung, Charlie
Anderson, Arianna
Flowers, Sara
Habel, Jill
Romesser, Paul B. https://orcid.org/0000-0001-8268-2903
Levine, Ross L. https://orcid.org/0000-0002-7884-1905
Lowe, Scott W.
Sadelain, Michel https://orcid.org/0000-0002-9031-8025
Beyaz, Semir https://orcid.org/0000-0003-4730-4012
Amor, Corina https://orcid.org/0000-0002-7654-6216
- License Information
-
More Information
Article History
Received: 31 July 2024
Accepted: 23 October 2025
First Online: 25 November 2025
Competing interests
: P.R. provides compensated professional services and activities for EMD Serono, Faeth Therapeutics, HPV Alliance and Natera Inc. He also offers uncompensated professional services and activities for 10x Genomics, XRad Therapeutics and the HPV Alliance and Anal Cancer Foundation non-profit organizations. R.L.L. is on the Supervisory board of Qiagen (compensation/equity), a co-founder/board member at Ajax (equity), a board member of the Mark Foundation for Cancer Research and is a scientific advisor to Mission Bio, Kurome, Syndax, Scorpion, Zentalis, Jubilant, Auron, Prelude and C4 Therapeutics; for each of these entities, he receives equity/compensation. He has received research support from the Cure Breast Cancer Foundation (with IP rights), Calico, Zentalis and Ajax, and has consulted/provided professional services for ECOG-ACRIN, Genome Canada, Goldman Sachs and Astra Zeneca. S.B. received research funding from Caper Labs, Elstar Therapeutics and Revitope Oncology for research unrelated to this study. S.W.L. is a founder and member of the scientific advisory board of Blueprint Medicines, Mirimus, ORIC Pharmaceuticals, Senescea and Faeth Therapeutics; is on the scientific advisory board of PMV Pharmaceuticals; and is a consultant for Fate Therapeutics. S.B. is an advisor for Caper Labs. S.B. and C.A. are listed as inventors on a patent application related to the regenerative effects of senolytic CAR T cells (63/510,997). S.L., M.S. and C.A. are listed as the inventor of several patent applications (62/800,188; 63/174,277; 63/209,941; 63/209,940; 63/209,915; 63/209,924; 17/426,728; 3,128,368; 20748891.7; 2020216486) related to senolytic CAR T cells. M.S. is also listed on other unrelated patents concerning CAR T technology. The other authors declare no competing interests.
